ISRG

Business Context and Reporting Period

Company: Intuitive Surgical, Inc. (ISRG)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2026
Business Overview: Intuitive develops, manufactures, and markets the da Vinci surgical systems and the Ion endoluminal system. The company operates in one reportable segment, managing business activities on a consolidated basis. As of June 30, 2026, the installed base included approximately 11,710 da Vinci systems and 1,096 Ion systems.

Key Financial Metrics

Note: Cash and investments balance of $8.63 billion as of June 30, 2026, includes cash, cash equivalents, short-term, and long-term investments.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 19% in Q2 2026 and 21% YTD 2026 compared to the prior year periods. Growth was driven by a 15% increase in da Vinci procedures and a 36% increase in Ion procedures.
• System Placements: da Vinci system placements rose 18% to 468 units in Q2 2026 (vs. 395 in Q2 2025), with 246 being da Vinci 5 systems. Ion placements remained relatively flat at 55 units.
• Acquisition Impact: On March 1, 2026, Intuitive acquired the da Vinci and Ion distribution businesses of ab medica, Abex, and Excelencia Robótica for approximately $533 million in cash. This added $218 million to goodwill and $219 million in intangible assets.
• Stock Repurchases: The company significantly increased buyback activity, repurchasing $1.44 billion of common stock in the first six months of 2026, compared to $181 million in the same period in 2025.
• Tariff Refunds: The company recognized $35.9 million in refunds related to IEEPA tariffs paid in prior periods during Q2 2026, which reduced cost of revenue.

Guidance, Outlook, and Risks

• Outlook: Management expects operating expenses to continue to increase due to investments in product development and personnel. Depreciation and amortization expenses are expected to rise in the remainder of 2026 due to recent capital expenditures and the acquisition.
• Tariff Environment: A 10% tariff on imports under Section 122 of the Trade Act of 1974 is currently in effect. While many products qualify for USMCA exclusions, imports from Germany (endoscopes) and China remain subject to tariffs. The company is monitoring potential supply chain disruptions and cost inflation.
• China Market: System demand in China has been adversely affected by competition from domestic manufacturers and a government campaign on systematic governance, leading to delayed tenders. New national pricing frameworks for robotic surgery are being implemented, though the impact has not yet been material.
• Legal Contingencies: The company faces ongoing antitrust litigation (e.g., SIS, Larkin Community Hospital) and product liability lawsuits. Management states it is unable to estimate the range of losses for these matters at this time.
• Regulatory: The company continues to seek regulatory clearances for the da Vinci 5 and da Vinci SP systems in various global markets, including expanded indications for cardiac and pediatric procedures.

Investor Verification Checklist

• Acquisition Integration: Verify the progress of integrating the newly acquired distribution businesses in Italy, Spain, and Portugal into the direct sales model.
• Tariff Exposure: Monitor the final resolution of IEEPA tariff refunds and the long-term impact of the 10% Section 122 tariffs on cost of revenue, particularly for German and Chinese imports.
• China Dynamics: Track the rollout of the National Healthcare Security Administration (NHSA) unified pricing framework and its effect on procedure volumes and instrument revenue in China.
• Lease Mix: Assess the impact of the increasing proportion of system placements under operating leases (54% of da Vinci placements in Q2) on revenue recognition volatility.
• Legal Outcomes: Review updates on the antitrust class action trial scheduled for September 2027 and the appeal of the SIS antitrust case.